CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $70.94B, higher than 95% of all stocks globally
- FinancialsAltman Z-Score 7: safe zone
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.56%
Annual Rate
USD 3.76Paid quarterly
Payout Ratio
8.7%Sustainable
Paying Dividends
2 yr
Last Ex-Dividend
May 20, 2026
Last Payment
Jun 4, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
70.94BUSDvs all stocks (USD)
Trailing P/E
16.58xvs Biotechnology peers
Revenue (TTM)
14.92BUSDvs all stocks (USD)
Profit Margin
29.65%vs Biotechnology peers
Beta
0.2360xvs all stocks
52-Week Change
24.04%vs all stocks
Forward Annual Dividend Yield
0.56%vs all stocks
Market Capitalization
70.94BUSDvs all stocks (USD)
Enterprise Value
63.03BUSDvs all stocks (USD)
Trailing P/E
16.58xvs Biotechnology peers
Forward P/E
12.40xvs Biotechnology peers
PEG Ratio
-2.13xvs Biotechnology peers
Price to Sales (TTM)
4.77xvs Biotechnology peers
Price to Book (MRQ)
2.20xvs Biotechnology peers
Enterprise to Revenue
4.22xvs Biotechnology peers
Enterprise to EBITDA
14.38xvs Biotechnology peers
Gross Margin
81.43%vs Biotechnology peers
Profit Margin
29.65%vs Biotechnology peers
Operating Margin
20.66%vs Biotechnology peers
Return on Assets (TTM)
6.13%vs Biotechnology peers
Return on Equity (TTM)
14.55%vs Biotechnology peers
Revenue (TTM)
14.92BUSDvs all stocks (USD)
Revenue per Share (TTM)
143.56USDUpdated Jul 19, 2026Quarterly Revenue Growth
19.00%vs Biotechnology peers
Gross Profit (TTM)
6.55BUSDvs all stocks (USD)
EBITDA (TTM)
5.12BUSDvs all stocks (USD)
Net Income (TTM)
4.42BUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-10.10%vs Biotechnology peers
Operating Cash Flow (TTM)
5.01BUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
3.27BUSDvs all stocks (USD)
Forward Annual Dividend Rate
3.76USDUpdated Jul 19, 2026Forward Annual Dividend Yield
0.56%vs all stocks
Trailing Annual Dividend Rate
3.64USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.54%vs all stocks
Payout Ratio
8.74%vs Biotechnology peers
Revenue
14.34BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
2.10BUSDFY2025 · Dec 31, 2025Gross Profit
12.24BUSDFY2025 · Dec 31, 2025Operating Income
3.70BUSDvs all stocks (USD)
Pre-tax Income
5.23BUSDFY2025 · Dec 31, 2025Income Tax Expense
725.80MUSDFY2025 · Dec 31, 2025Net Income
4.50BUSDFY2025 · Dec 31, 2025EBIT
5.27BUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
5.00BUSDFY2025 · Dec 31, 2025Research & Development
5.85BUSDFY2025 · Dec 31, 2025Selling, General & Administrative
2.70BUSDFY2025 · Dec 31, 2025Other Operating Expenses
-10.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
716.80MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
43.80MUSDFY2025 · Dec 31, 2025EPS (Basic)
43.07USDFY2025 · Dec 31, 2025EPS (Diluted)
41.48USDFY2025 · Dec 31, 2025Basic Shares Outstanding
104.60MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
104.60MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
4.50BUSDFY2025 · Dec 31, 2025Operating Cash Flow
6.30BUSDFY2025 · Dec 31, 2025Free Cash Flow
6.30BUSDDerived from operating cash flow minus capital expenditure. This filing charges 543.7M of depreciation against 0 of capital expenditure, and its own free-cash-flow line reads 3.77B.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.12BUSDFY2025 · Dec 31, 2025Interest Paid
41.60MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
4.50BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
543.70MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-785.40MUSDFY2025 · Dec 31, 2025Stock-based Compensation
993.70MUSDFY2025 · Dec 31, 2025Other Non-cash Items
135.50MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
498.10MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
736.80MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-327.00MUSDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Net Intangibles (CF)
-315.30MUSDFY2025 · Dec 31, 2025Net Acquisitions
-3.30MUSDFY2025 · Dec 31, 2025Purchase of Investments
-10.96BUSDFY2025 · Dec 31, 2025Sale of Investments
11.55BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
584.60MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-3.97BUSDFY2025 · Dec 31, 2025Common Dividends Paid
-370.30MUSDFY2025 · Dec 31, 2025Other Financing Charges
-10.30MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-3.72BUSDFY2025 · Dec 31, 2025Shares Outstanding
105.02MSharesUpdated Jul 19, 2026Float Shares
97.67MSharesUpdated Jul 19, 2026Shares Short
3.49MSharesUpdated Jul 19, 2026Short Ratio
3.20daysvs all stocks
Short % of Shares Outstanding
3.52%vs all stocks
% Held by Insiders
2.03%vs all stocks
% Held by Institutions
93.45%vs all stocks
Total Cash (MRQ)
8.75BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
86.04USDUpdated Jul 19, 2026Total Debt (MRQ)
2.71BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0861xvs Biotechnology peers
Current Ratio (MRQ)
3.56xvs Biotechnology peers
Book Value per Share (MRQ)
308.32USDUpdated Jul 19, 2026Total Assets
40.56BUSDvs all stocks (USD)
Total Current Assets
18.02BUSDFY2025 · Dec 31, 2025Total Liabilities
9.30BUSDFY2025 · Dec 31, 2025Total Non-current Assets
22.54BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.93BUSDFY2025 · Dec 31, 2025Total Current Liabilities
4.37BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.12BUSDFY2025 · Dec 31, 2025Other Short-term Investments
5.49BUSDFY2025 · Dec 31, 2025Accounts Receivable
5.74BUSDFY2025 · Dec 31, 2025Inventory
3.20BUSDFY2025 · Dec 31, 2025Accounts Payable
939.00MUSDFY2025 · Dec 31, 2025Deferred Revenue
553.00MUSDFY2025 · Dec 31, 2025Long-term Debt
2.71BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
2.02BUSDFY2025 · Dec 31, 2025Common Stock (Book)
100.00KUSDFY2025 · Dec 31, 2025Retained Earnings
35.80BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
31.26BUSDvs all stocks (USD)
Treasury Stock
18.61BUSDFY2025 · Dec 31, 202552-Week Low
541.00USDUpdated Jul 19, 202652-Week High
821.11USDUpdated Jul 19, 202652-Week Change
24.04%vs all stocks
Beta
0.2360xvs all stocks
50-Day MA
646.34USDUpdated Jul 19, 2026200-Day MA
703.76USDUpdated Jul 19, 2026Avg 10-Day Volume
705.91KSharesUpdated Jul 19, 2026Avg 30-Day Volume
967.17KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
40.94USDUpdated Jul 19, 2026Other Income / Expense
855.70MUSDFY2025 · Dec 31, 20257 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 7: safe zoneNotable
Altman Z-Score: 7.00
High earnings qualityNotable
Earnings Quality Score: 0.64
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $70.94B, higher than 95% of all stocks globallySignificant
Market cap (USD): 70,943,524,564Global P95: 25,614,208,870.135
Revenue is $14.92B, higher than 95% of all stocks globallySignificant
Revenue (USD): 14,919,600,128Global P95: 14,667,937,174.886
Levered free cash flow is $3.27B, higher than 95% of all stocks globallySignificant
Levered free cash flow (USD): 3,273,349,888Global P95: 1,123,592,359.78
Companies that share the same coordination system — how they create, deliver, or capture value.
Merck KGaA
Tier 1ProductionApproval-Gated PipelineRuleFlow
Boston Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
argenx SE
Tier 1ProductionApproval-Gated PipelineRule
Beigene Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bayer AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
UCB SA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Siemens Healthineers AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Samsung Biologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Edwards Lifesciences Corporation
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Garmin Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated
Harmony Biosciences Holdings, Inc.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated
Thyrocare Technologies Ltd.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated